Monoclonal "Sameness" To Be Defined By Complementarity Regions - FDA
Executive Summary
"Sameness" for monoclonal antibodies under orphan drug regulations will be defined solely by the complementarity determining regions of the proteins, an FDA draft guidance entitled "Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations" states.
You may also be interested in...
Orphan Drug "Sameness" Definition Update Will Recognize New Science
FDA is planning to update its definitions of orphan drug "sameness" and "difference" to address new issues related to biotechnology and biologics, FDA Office of Orphan Products Development Director Marlene Haffner said at a May 5 workshop in Brussels on rare diseases and orphan drugs.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials